191 related articles for article (PubMed ID: 18560011)
1. Enzymatic and structural analysis of the I47A mutation contributing to the reduced susceptibility to HIV protease inhibitor lopinavir.
Sasková KG; Kozísek M; Lepsík M; Brynda J; Rezácová P; Václavíková J; Kagan RM; Machala L; Konvalinka J
Protein Sci; 2008 Sep; 17(9):1555-64. PubMed ID: 18560011
[TBL] [Abstract][Full Text] [Related]
2. Structural analysis of an HIV-1 protease I47A mutant resistant to the protease inhibitor lopinavir.
Kagan RM; Shenderovich MD; Heseltine PN; Ramnarayan K
Protein Sci; 2005 Jul; 14(7):1870-8. PubMed ID: 15937277
[TBL] [Abstract][Full Text] [Related]
3. Acquired HIV-1 Protease Conformational Flexibility Associated with Lopinavir Failure May Shape the Outcome of Darunavir Therapy after Antiretroviral Therapy Switch.
Eche S; Kumar A; Sonela N; Gordon ML
Biomolecules; 2021 Mar; 11(4):. PubMed ID: 33805099
[TBL] [Abstract][Full Text] [Related]
4. Crystallographic study of multi-drug resistant HIV-1 protease lopinavir complex: mechanism of drug recognition and resistance.
Liu Z; Yedidi RS; Wang Y; Dewdney TG; Reiter SJ; Brunzelle JS; Kovari IA; Kovari LC
Biochem Biophys Res Commun; 2013 Jul; 437(2):199-204. PubMed ID: 23792096
[TBL] [Abstract][Full Text] [Related]
5. Drug-resistant molecular mechanism of CRF01_AE HIV-1 protease due to V82F mutation.
Liu X; Xiu Z; Hao C
J Comput Aided Mol Des; 2009 May; 23(5):261-72. PubMed ID: 19219633
[TBL] [Abstract][Full Text] [Related]
6. Amprenavir complexes with HIV-1 protease and its drug-resistant mutants altering hydrophobic clusters.
Shen CH; Wang YF; Kovalevsky AY; Harrison RW; Weber IT
FEBS J; 2010 Sep; 277(18):3699-714. PubMed ID: 20695887
[TBL] [Abstract][Full Text] [Related]
7. Multidrug resistance to HIV-1 protease inhibition requires cooperative coupling between distal mutations.
Ohtaka H; Schön A; Freire E
Biochemistry; 2003 Nov; 42(46):13659-66. PubMed ID: 14622012
[TBL] [Abstract][Full Text] [Related]
8. Molecular basis for substrate recognition and drug resistance from 1.1 to 1.6 angstroms resolution crystal structures of HIV-1 protease mutants with substrate analogs.
Tie Y; Boross PI; Wang YF; Gaddis L; Liu F; Chen X; Tozser J; Harrison RW; Weber IT
FEBS J; 2005 Oct; 272(20):5265-77. PubMed ID: 16218957
[TBL] [Abstract][Full Text] [Related]
9. Effect of flap mutations on structure of HIV-1 protease and inhibition by saquinavir and darunavir.
Liu F; Kovalevsky AY; Tie Y; Ghosh AK; Harrison RW; Weber IT
J Mol Biol; 2008 Aug; 381(1):102-15. PubMed ID: 18597780
[TBL] [Abstract][Full Text] [Related]
10. Human immunodeficiency virus type 1 genotypic and pharmacokinetic determinants of the virological response to lopinavir-ritonavir-containing therapy in protease inhibitor-experienced patients.
Masquelier B; Breilh D; Neau D; Lawson-Ayayi S; Lavignolle V; Ragnaud JM; Dupon M; Morlat P; Dabis F; Fleury H;
Antimicrob Agents Chemother; 2002 Sep; 46(9):2926-32. PubMed ID: 12183249
[TBL] [Abstract][Full Text] [Related]
11. Crystal structures of HIV protease V82A and L90M mutants reveal changes in the indinavir-binding site.
Mahalingam B; Wang YF; Boross PI; Tozser J; Louis JM; Harrison RW; Weber IT
Eur J Biochem; 2004 Apr; 271(8):1516-24. PubMed ID: 15066177
[TBL] [Abstract][Full Text] [Related]
12. Characterization of resistant HIV variants generated by in vitro passage with lopinavir/ritonavir.
Mo H; Lu L; Dekhtyar T; Stewart KD; Sun E; Kempf DJ; Molla A
Antiviral Res; 2003 Aug; 59(3):173-80. PubMed ID: 12927307
[TBL] [Abstract][Full Text] [Related]
13. A synergy of activity, stability, and inhibitor-interaction of HIV-1 protease mutants evolved under drug-pressure.
Khan SN; Persons JD; Guerrero M; Ilina TV; Oda M; Ishima R
Protein Sci; 2021 Mar; 30(3):571-582. PubMed ID: 33314454
[TBL] [Abstract][Full Text] [Related]
14. Genotypic and phenotypic cross-resistance patterns to lopinavir and amprenavir in protease inhibitor-experienced patients with HIV viremia.
Paulsen D; Liao Q; Fusco G; St Clair M; Shaefer M; Ross L
AIDS Res Hum Retroviruses; 2002 Sep; 18(14):1011-9. PubMed ID: 12396453
[TBL] [Abstract][Full Text] [Related]
15. Interactions of different inhibitors with active-site aspartyl residues of HIV-1 protease and possible relevance to pepsin.
Sayer JM; Louis JM
Proteins; 2009 May; 75(3):556-68. PubMed ID: 18951411
[TBL] [Abstract][Full Text] [Related]
16. P1 and P1' para-fluoro phenyl groups show enhanced binding and favorable predicted pharmacological properties: structure-based virtual screening of extended lopinavir analogs against multi-drug resistant HIV-1 protease.
Yedidi RS; Liu Z; Kovari IA; Woster PM; Kovari LC
J Mol Graph Model; 2014 Feb; 47():18-24. PubMed ID: 24291501
[TBL] [Abstract][Full Text] [Related]
17. A contribution to the drug resistance mechanism of darunavir, amprenavir, indinavir, and saquinavir complexes with HIV-1 protease due to flap mutation I50V: a systematic MM-PBSA and thermodynamic integration study.
Leonis G; Steinbrecher T; Papadopoulos MG
J Chem Inf Model; 2013 Aug; 53(8):2141-53. PubMed ID: 23834142
[TBL] [Abstract][Full Text] [Related]
18. Mutational patterns and correlated amino acid substitutions in the HIV-1 protease after virological failure to nelfinavir- and lopinavir/ritonavir-based treatments.
Garriga C; Pérez-Elías MJ; Delgado R; Ruiz L; Nájera R; Pumarola T; Alonso-Socas Mdel M; García-Bujalance S; Menéndez-Arias L;
J Med Virol; 2007 Nov; 79(11):1617-28. PubMed ID: 17854027
[TBL] [Abstract][Full Text] [Related]
19. Prevalence and impact of HIV-1 protease mutation L76V on lopinavir resistance.
de Mendoza C; Garrido C; Corral A; Zahonero N; Soriano V
AIDS; 2008 Jan; 22(2):311-3. PubMed ID: 18097236
[TBL] [Abstract][Full Text] [Related]
20. Improving lopinavir genotype algorithm through phenotype correlations: novel mutation patterns and amprenavir cross-resistance.
Parkin NT; Chappey C; Petropoulos CJ
AIDS; 2003 May; 17(7):955-61. PubMed ID: 12700444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
